Deuteroncology
Clinical trials sponsored by Deuteroncology, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New MET inhibitor DO-2 enters human trials for Hard-to-Treat cancers Results expected Sep 2027 (estimated)